Eli Lilly inks deal with ImmuNext to jointly develop therapies for autoimmune diseases

Eli Lilly and ImmuNext announced a collaboration to jointly study a preclinical novel target that could facilitate the development of new treatments for autoimmune disorders that regulate immune cell metabolism. Eli Lilly vice president of immunology Ajay Nirula commented "regulating the metabolism of immune cells is a promising approach to treating these diseases."

Under the agreed terms, Eli Lilly will make an upfront payment of $40 million to ImmuNext, gaining an exclusive global license to develop and commercialise the immunometabolism target. As part of the deal, ImmuNext is eligible to receive as much as $565 million in milestones, as well as mid-single-digit to low-double-digit royalties on sales.

In addition, Eli Lilly and ImmuNext will establish a three-year research collaboration in support of development of the target.  

The deal with Eli Lilly builds on previous agreements ImmuNext signed with Rocheand Sanofi focused on the development of treatments for autoimmune disorders. ImmuNext has also partnered with Johnson & Johnson on the development of immunotherapies for cancer.

Register as Visitor to CPhI China 2019!

-----------------------------------------------------------------------
Editor's Note:

To apply for becoming a contributor of En-CPhI.cn,

welcome to send your CV and sample works to us,

Email: Julia.Zhang@ubmsinoexpo.com.